Lisata Therapeutics Inc (LSTA)

[Viperciara]

Carl Ichan thinks Neostem is good or why out of all the Stem Cell companies would he pick NeoStem?

Mount Sinai researchers who received an $8.8 million grant Health Pulse Subscription Needed: from the New York State Cell Science Program in January have forged an alliance with two companies to help accelerate their project beyond the lab. NeoStem, a Manhattan company, and Alameda, Calif.-based AllCells will contribute to a 10-person team tasked with moving the research to clinical trials. The group is led by Dr. Ronald Hoffman, professor of medicine, hematology and medical oncology at the Icahn School of Medicine. It has four years, starting July 1, to accomplish its goal of expanding the number of stem cells collected in cord blood so that the number of cells is adequate to treat adults with chemotherapy-resistant blood cancers and other genetic diseases. Dr. Hoffman has been working on cord-blood expansion since the 1980s, and his team has developed a technique effective in the lab. NeoStem and AllCells will help perform the technique on a larger scale while adhering to federal manufacturing standards. "My concept was, since we're not an industrial corporation, it was probably best to interact with companies that are used to dealing with cellular products in an industrial fashion," Dr. Hoffman said, adding that the collaboration is unique for academic research, which can be "a very individualistic type of operation."

Whole story here>> http://www.crainsnewyork.com/article/20150415/PULSE/150419928/gnyha-1199-seiu-confront-labor-pain